Clinical Trials
The Parkinson's Progression Markers Initiative (PPMI) 2.0 Clinical -Establishing a Deeply Phenotyped PD Cohort
Lead Researcher: Ruth Schneider
The Parkinson Progression Marker Initiative 2.0 (PPMI 2.0) is a longitudinal, observational,
multi-center natural history study to assess progression of clinical features, digital
outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression
in study participants with manifest PD, prodromal PD, and healthy controls.
The overall goal of the study is to identify markers of disease progression for use in
clinical trials of therapies to reduce progression of PD disability.
View Study Details
Publications
Journal Articles
2023
Dorsey ER, Zafar M, Lettenberger SE, Pawlik ME, Kinel D, Frissen M, Schneider RB, Kieburtz K, Tanner CM, De Miranda BR, Goldman SM, Bloem BR. "Trichloroethylene: An Invisible Cause of Parkinson's Disease?" Journal of Parkinson's disease.. 2023 13(2):203-218.
10/2022
Jensen-Roberts S, Myers TL, Auinger P, Cannon P, Rowbotham HM, Coker D, Chanoff E, Soto J, Pawlik M, Amodeo K, Sharma S, Valdovinos B, Wilson R, Sarkar A, McDermott MP, Alcalay RN, Biglan K, Kinel D, Tanner C, Winter-Evans R, Augustine EF, Holloway RG, Dorsey ER, Schneider RB. "A Remote Longitudinal Observational Study of Individuals at Genetic Risk for Parkinson Disease: Baseline Results." Neurology. Genetics.. 2022 Oct; 8(5):e200008. Epub 2022 Aug 11.
9/21/2022
Liu Y, Zhang G, Tarolli CG, Hristov R, Jensen-Roberts S, Waddell EM, Myers TL, Pawlik ME, Soto JM, Wilson RM, Yang Y, Nordahl T, Lizarraga KJ, Adams JL, Schneider RB, Kieburtz K, Ellis T, Dorsey ER, Katabi D. "Monitoring gait at home with radio waves in Parkinson's disease: A marker of severity, progression, and medication response." Science translational medicine.. 2022 Sep 21; 14(663):eadc9669. Epub 2022 Sep 21.
VIEW ALL PUBLICATIONS